RSV, and influenza show continued safety and substantial effectiveness against hospitalization across various populations.

The American Academy of Pediatrics has issued updated recommendations for RSV prevention in infants and high-risk young children.

Federal regulators have begun a safety review of 2 RSV medicines used to protect infants, even though no safety problems have been reported.

You hear about the flu vaccine, the COVID-19 vaccine, even the pneumonia vaccine, but in 2023, the FDA approved the first RSV ...

NEXSPIKE is Moderna's third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and ...

You recently posted a couple of articles about the respiratory syncytial virus (RSV) vaccine and the benefits versus the ...

A number of diseases tend to peak in the winter, thanks to indoor gatherings that help germs spread. The list includes not ...

Researchers evaluated the real-world effectiveness of nirsevimab in preventing ICU admission and acute respiratory failure associated with RSV among infants.

The decision applies to adolescents and adults and aligns with earlier US authorization for higher-risk groups.

GSK said on Friday a panel of the European Medicines Agency had backed the use of its respiratory syncytial virus (RSV) vaccine, Arexvy, for all adults above the age of 18, paving the way for broader ...

FDA turns up the heat: Federal regulators are requesting more safety information from drugmakers on products meant to protect ...